Advanced Filters
noise
Found 296 clinical trials
J James Wu

Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer

This study is being done to help researchers learn more about and successfully diagnose cancer using blood samples and tissue samples from surgeries in patients with suspicious thyroid nodules or thyroid cancer. Diagnosing cancer in this way, as opposed to biopsies, may be less invasive to the patient. Analyzing blood …

18 years of age All Phase N/A
N Nina M Wilpert, MD/PhD

Register for Patients With Thyroid Hormone Resistance.

Thyroid hormones (TH) play a pivotal role in the development and function of the mammalian brain. Patients with impaired thyroid hormone transport into the brain tissue or in the case of defective local thyroid hormone receptor (collectively referred to as thyroid hormone resistance) subsequently experience psychomotor disabilities. The "DEEPTYPE" registry …

years of age All Phase N/A
L Lawrence DIERICKX, MD

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.

18 years of age All Phase N/A

Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer

To evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer

18 years of age All Phase N/A
M Mesut YILMAZ, Dr.

Multisensory Methods and Patient Comfort in Thyroid Biopsy

This quasi-experimental study aims to determine the effect of watching an therapeutic video on patients' pain, anxiety, and comfort levels during thyroid biopsy procedures. The study will be conducted in the interventional radiology unit of Muş State Hospital between July 30, 2025, and August 28, 2026. A total of 68 …

18 - 90 years of age All Phase N/A
N Nathalie Sarup Panduro, MD

Microvascular Profiling of Nodules in the Thyroid Gland

The purpose of this study is to examine tiny blood vessels in different thyroid nodules using advanced ultrasound. In the long term, we hope this can help doctors better tell the difference between types of nodules and more accurately decide who may need surgery.

18 years of age All Phase N/A
L Liang Shi

Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer

Exogenous injection of recombinant human thyroid stimulating hormone (rhTSH) can elevate TSH in the short term (2 days) to meet the requirements of diagnostic 131I SPECT/CT whole-body scans. Antiangiogenic tyrosine kinase inhibitors (TKI) couuld alter the uptake of radioactive 131I in locally advanced or metastatic differentiated thyroid cancer. rhTSH can …

18 - 75 years of age All Phase N/A
M Marialuisa Appetecchia, MD

Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)

Thyroid nodules present a variable risk of malignancy depending on the cytological result obtained from the ultrasound-assisted thyroid fine needle aspiration biopsy. According to the Italian Cytology classification SIAPEC-IAP 2014, the TIR3A nodules are indeterminate nodules with a risk of malignancy lower than 10%. Clinical and instrumental follow-up is recommended …

18 years of age All Phase N/A
S Sara Helmig, MD

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, …

2 - 99 years of age All Phase 2
J Joanna Rymuza, MD, PHD

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease.

18 - 80 years of age All Phase N/A

Simplify language using AI